Ciaran O'Leary is the son of former IDA Ireland chief Barry O'Leary, giving him an unusually deep family-level perspective on how global tech and foreign direct investment decisions get made, which informs his approach to European startup ecosystems. He has organized BlueYard's investment thesis around three specific fundamental forces—decentralisation of markets, democratisation of capabilities, and liberation of data—for nearly a decade, backing technically ambitious infrastructure companies like Protocol Labs/Filecoin, Meatable, and Bit Bio rather than incremental software plays.

• Deep interest in the foundational layers of the crypto economy, particularly projects that solve infrastructure challenges or improve user experience within the Ethereum ecosystem. For example, he frequently highlights portfolio companies that act as connective tissue for applications, such as a developer tool that simplifies user onboarding and asset management across different platforms to help bringing crypto to mass adoption.
• Enthusiasm for frontier technology and scientific breakthroughs that transition from science fiction to reality. This includes backing startups working on advanced material science, nuclear fusion energy, and programmable chemistry for drug discovery that fundamentally changes how molecules are designed and manufactured.
• A focus on the intersection of artificial intelligence with other hard constraints, such as physical compute limitations or blockchain networks. He actively discusses investments in decentralized networks that coordinate GPU resources for AI processing rather than just software applications alone, viewing these networks as efficient ways to manage capital and compute power.
• Commitment to funding dual-use technologies and modern defense capabilities, specifically framing them as necessary for global deterrence. He has publicly supported companies building next-generation deep strike capabilities and platforms intended to fill gaps in non-nuclear security strategies because he believes defensive strategies alone are insufficient.
• Investment in programmable biology and advanced therapeutics that aim to extend human life or defend against biological threats. His recent activity includes support for teams developing systemically administered RNA medicines to protect memories and novel methods for viral defense.
• Strong belief in the potential of the European technology ecosystem, often encouraging technical talent in the region to transition into entrepreneurship. He pushes back against pessimistic narratives regarding European innovation, advocating for a long-term view of the continent's trajectory and supporting programs that help technical minds become founders.